MDT

MEDTRONIC PLC

Healthcare | Mega Cap

$1.38

EPS Forecast

$8,984

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-04-30

Medtronic’s Fiscal Year Finale: A Strong Q4 Performance That’s No Surgery for Investors

GALWAY, Ireland – May 21, 2025 – Medtronic plc (NYSE: MDT) has just unveiled its fourth quarter financial results, and spoiler alert: they’re looking pretty good. The company has reported an impressive revenue forecast, showcasing a robust finish to its fiscal year 2025.

Quarterly Highlights: A Clean Bill of Health

Medtronic's Q4 revenue clocked in at $8.9 billion, marking a 3.9% increase as reported and a 5.4% organic jump. The company’s GAAP diluted EPS rose by a staggering 67% to $0.82, while the non-GAAP diluted EPS stood at $1.62, up 11%. If you’re keeping score, that’s a healthy earnings surprise for those who had an EPS consensus of lower expectations.

The company also highlighted a significant operating margin improvement, with a 380 basis point increase for the quarter. All in all, the operating profit surged to $1.4 billion, which is a 36% boost year-over-year. Not too shabby for a company that’s been navigating the choppy waters of healthcare technology.

Year-End Review: Fiscal Year 2025 in Perspective

Diving deeper into the annual results, Medtronic reported total revenue of $33.5 billion for FY25, which translates to a 3.6% increase as reported and 4.9% organic growth. The GAAP diluted EPS for the year hit $3.61, reflecting a 31% increase, while the non-GAAP figure rose by 6% to $5.49. It seems Medtronic has really taken its medicine and is thriving.

Interestingly, the operating profit for the year reached $6.0 billion, up 16%, which underscores the company’s strong performance across its key franchises, including Pulsed Field Ablation and TAVR.

Dividends and Shareholder Returns: A Heartfelt Gesture

In a move that should warm the hearts of investors, Medtronic announced a dividend increase for Q1 FY26 to $0.71 per share, implying an annualized rate of $2.84 per share. This marks the 48th consecutive year of dividend increases, a testament to the company’s commitment to returning value to its shareholders.

For those keeping track, the company returned $6.3 billion to shareholders in FY25, which is certainly not pocket change. It reflects a strategy that prioritizes investor confidence while continuing to invest in growth areas.

The Road Ahead: What Does This Mean for Medtronic and Its Peers?

Medtronic's strong Q4 and fiscal year results could portend a bullish trend for the healthcare sector, especially as other companies look to navigate similar challenges. Key franchises like Cardiac Ablation Solutions and the recent FDA submissions for innovative products suggest that the company is not just resting on its laurels.

Furthermore, with a healthy cash flow of $7.0 billion from operations, Medtronic is well-positioned to invest in R&D and strategic acquisitions, potentially setting the stage for further growth and innovation. In a sector where technological advancements are pivotal, Medtronic’s ability to adapt and lead may offer a competitive edge against peers.

As we wrap up this financial examination, it’s clear that Medtronic's fiscal year 2025 results not only reflect strong operational performance but also set an optimistic tone for the future. With dividends up and profits soaring, investors may find this company’s journey to be less of a medical drama and more of a success story.